FALCO HOLDINGS Co., Ltd.
Q1 2027 Consolidated Financial Results under Japanese GAAP (Interim)
For the first quarter of the fiscal year ending March 2027, consolidated results: net sales 11,003 million yen (YoY +0.7%), operating income 546 million yen (YoY +19.9%), ordinary income 637 million yen (YoY +18.8%), and net income attributable to owners of parent 385 million yen (YoY +20.2%). The Clinical Testing segment led performance, while the Dispensing Pharmacy segment saw a decline in sales due to a reduction in store count; ICT remained solid but costs increased. The full-year forecast is unchanged from the prior outlook.
Key Figures
- Net sales: 11,003百万円（YoY +0.7%）
- Operating income: 546百万円（YoY +19.9%）
- Ordinary income: 637百万円（YoY +18.8%）
AI要約
Business Performance Overview
For the first quarter of the fiscal year ending March 2027, total net sales amounted to 11,003 million yen, up 0.7% YoY. Growth in the Clinical Testing segment drove overall performance, with operating income of 546 million yen, up 19.9% YoY; ordinary income of 637 million yen, up 18.8% YoY; and quarterly net income attributable to owners of parent of 385 million yen, up 20.2% YoY. By segment, Clinical Testing remained solid, Dispensing Pharmacy declined 1.3% due to decreased store count, and ICT rose 15.5%. The full-year outlook remains as previously announced.
Financial Position and Outlook
As of quarter-end, total assets were 37,127 million yen, net assets were 25,383 million yen, and the equity ratio was 68.2%. Cash and deposits totaled 8,684 million yen, current assets were 18,649 million yen, current liabilities were 8,477 million yen, and total liabilities were 11,743 million yen. The second-quarter cumulative forecast was not disclosed. In the long term, the Company will continue to promote foundational and growth businesses under the FALCO VISION 2030 and FALCO INNOVATION 2026 plans.
Falco Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
